NIH SBIR-STTR
South Rampart Pharma receives $1.9M NIH STTR Fast-Track Grant

PAIN RELIEF INNOVATION

South Rampart Pharma is a clinical-stage life science company that aims to advance the safe treatment of pain by developing new small-molecule solutions that can overcome many risks associated with current pain medicines. The Company’s pipeline of novel compounds have effectively reduced both pain and fever in preclinical studies without the liver and kidney toxicity of current non-opioid analgesics. The Company’s lead program SRP-3D (Diethylamide [DA]), is currently in a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics with data expected in the second half of 2022.

Play Video

Watch our video

South Rampart Pharma is featured by NINDS, NIH Small Business Program to support small businesses developing products addressing unmet clinical and research needs.

South Rampart Pharma is advancing the treatment of pain by developing new, small-molecule solutions that have the potential to overcome many risks associated with current pain medicines.

Technology

Pipeline

Global Need